Seth Sandeshinsider trades
In SEC Form 4 filings, Seth Sandesh is listed as Chief Executive Officer of Actinium Pharmaceuticals, Inc. (ATNM). Seth Sandesh reported no open-market purchases or sales in the last 90 days. The latest Form 4 transaction on record was filed on Sep 4.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| ATNMActinium Pharmaceuticals, Inc. | Chief Executive Officer | 3 | Sep 4 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-04
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| ATNMActinium Pharmaceuticals, Inc. | Sep 2 | Sep 4 | A | 753,600 | $0.00 | $0 | 938,081 | No | Form 4 |
| ATNMActinium Pharmaceuticals, Inc. | Sep 2 | Sep 4 | A | 1,027,274 | $0.00 | $0 | 1,965,355 | No | Form 4 |
| ATNMActinium Pharmaceuticals, Inc. | Sep 2 | Sep 4 | A · derivative | 1,130,400 | $1.00 | $1,130,400 | 1,130,400 | No | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.